Brun Guinda David, Callen García Óscar, Ondiviela Pérez Jorge, Gracia Aznarez María, Artero Bello Pilar, Rivero Fernandez Elena, Marquina Barcos Adolfo, Villarroel Salcedo Maite
Servicio de Cardiología, Hospital General San Jorge, Huesca, Spain.
Servicio de Cardiología, Hospital de Jaca, Huesca, Spain.
Future Cardiol. 2018 May;14(3s):39-45. doi: 10.2217/fca-2018-0025.
To analyze clinical profile and management of patients with nonvalvular atrial fibrillation treated with rivaroxaban in clinical practice according to age and to ascertain rates of thromboembolic and bleeding events during rivaroxaban therapy.
Retrospective study of nonvalvular atrial fibrillation patients that started rivaroxaban therapy between May 2013 and February 2017 in the cardiology department of two hospitals from Huesca, Spain.
A total of 137 patients (mean age 78.2 ± 8.9 years; CHADS-VASc 3.5 ± 1.3; HAS-BLED 1.6 ± 0.7) were included. Comorbidity was common. After a mean duration of treatment of 30.5 ± 17.2 months, no strokes were reported. Rates of transient ischemic attack, major bleeding and intracranial bleeding were low.
In this cohort of elderly and highly comorbid patients treated with rivaroxaban, rates of thromboembolic and bleeding events were low.
根据年龄分析临床实践中接受利伐沙班治疗的非瓣膜性心房颤动患者的临床特征及治疗情况，并确定利伐沙班治疗期间血栓栓塞和出血事件的发生率。
对2013年5月至2017年2月期间在西班牙韦斯卡市两家医院心内科开始接受利伐沙班治疗的非瓣膜性心房颤动患者进行回顾性研究。
共纳入137例患者（平均年龄78.2±8.9岁；CHADS-VASc评分为3.5±1.3；HAS-BLED评分为1.6±0.7）。合并症很常见。平均治疗时间为30.5±17.2个月，未报告中风病例。短暂性脑缺血发作、大出血和颅内出血的发生率较低。
在这一接受利伐沙班治疗的老年且合并症多的患者队列中，血栓栓塞和出血事件的发生率较低。
